CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 48 enrolled
Drug / intervention
Sitagliptin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02312063
NCT02312063Phase 4Completed
CompareCT.gov

Dietary Impacts on Glucose-lowering Effects of Sitagliptin in Type 2 Diabetes: a Multicenter, Randomized, Prospective, Open-label, Clinical Trial

Kansai Electric Power Hospital·interventional·Posted Dec 9, 2014·Updated Jul 1, 2019

In Brief

A Phase 4 clinical trial evaluating Sitagliptin and Glimepiride for Diabetes Mellitus, Type 2. Completed, enrolled 48 participants across 2 sites.

Detailed Summary

In a prospective, randomized case-controlled study, the investigators hope to demonstrate a positive correlation of plasma levels of EPA and DHA as well as fish intake with the HbA1c-lowering effect of sitagliptin but not with the active comparator glimepiride.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesJapan
CollaboratorsSaiseikai Noe Hospital Osaka

Timeline

Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
First PostedDec 9, 2014
Enrollment StartFeb 1, 2015
Primary CompletionMay 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 11.6 years ago

Interventions

Sitagliptindrug

Glimepiridedrug